A thermosensitive hydroxybutyl chitosan hydrogel as a potential co-delivery matrix for drugs on keloid inhibition. Issue 22 (18th May 2016)

• Record Type: Journal Article
• Authors: Bao, Zixian; Gao, Ping; Xia, Guixue; Wang, Zhiguo; Kong, Ming; Feng, Chao; Cheng, Xiaojie; Liu, Ya; Chen, Xiguang
• Is Part Of: Journal of materials chemistry. Volume 4:Issue 22(2016)
• Page Start: 3936
• Page End: 3944
• Publication Date: 2016-05-18
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c6tb00378h
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : A thermosensitive hydroxybutyl chitosan hydrogel could be used as a potential co-delivery matrix for drugs on keloid inhibition. Abstract : Keloid is a kind of unique human fibroproliferative dermal disease, and there are still no optimal treatment methods for it. In the present study, a thermosensitive hydroxybutyl chitosan (HBC) hydrogel as a co-delivery matrix for 5-fluorouracil (5-FU) and dexamethasone sodium phosphate (DEXSP) in keloid treatment was developed. The gelation temperature of the HBC hydrogel was observed to be 25.7 °C by rheology analysis. The HBC hydrogel showed sustained drug release capacity (5-FU, 89.3 ± 3.4%; DEXSP, 95.6 ± 3.9%) for drug delivery. The HBC hydrogel was shown to be cytocompatible, while the dual drug-loaded HBC hydrogel could suppress the proliferation of keloid fibroblasts (KFs). The keloid biopsies treated with the dual drug-loaded hydrogel could be inhibited through the efficient suppression of VEGF expression within 7 days. The results suggested that the HBC hydrogel could be applied as a potential co-delivery matrix for drugs in the keloid therapy field.